Definitive clinical trials of new chemotherapies for treating tuberculosis (TB) require following subjects until at least 6 months after treatment discontinuation to assess for durable cure, making these trials expensive and lengthy. Surrogate endpoints relating to treatment failure and relapse are currently limited to sputum microbiology, which has limited sensitivity and specificity. We prospectively assessed radiographic changes using 2-deoxy-2-[
INTRODUCTION
A major focus of tuberculosis (TB) research is the identification of a sensitive and specific biomarker that can not only determine disease stage (latent, active, cured) but also quantitate the risk of disease progression from latent to active and identify active disease that is either cured or heading for relapse. A number of candidate biomarkers are currently under study. The most widely proposed biomarker to predict relapse-free cure is 2-month sputum culture conversion status (1) . However, this biomarker is far from ideal for predicting relapse, with one meta-analysis reporting a pooled sensitivity of 40% [95% confidence interval (CI), 25 to 56%] and specificity of 85% (95% CI, 77 to 91%) for predicting relapse (2) . More severe disease and lung cavities on baseline chest x-ray have also been associated with an increased risk of relapse (3) . Yet, prospective studies using sputum conversion at 2 months and absence of cavities to shorten treatment have not proven successful (4, 5) . Two-month sputum culture conversion has also been the basis of recent drug approvals in spite of literature demonstrating its poor performance as a surrogate endpoint for patient outcome (6) . Better biomarkers for both patient management and trial-level surrogacy are clearly needed.
2-Deoxy-2-[ 18 F]-fluoro-D-glucose (FDG) positron emission tomography/computed tomography (PET/CT) scans are well established in cancer trials to stage disease and predict outcomes (7) (8) (9) (10) (11) (12) (13) . A number of case reports and small studies have also used PET/CT scans for TB diagnosis or to assess treatment response. Diagnostic studies have focused on determining the extent of TB disease (14, 15) , differentiating TB from cancer (15) (16) (17) (18) , or differentiating active from latent TB (15, 19, 20) . Studies that assessed treatment response performed a baseline PET/CT scan and compared that to a follow-up PET/CT scan during treatment (19, 21, 22) and/or after treatment completion (16, 19, 23, 24) to monitor or confirm treatment response at these different time points. To our knowledge, no published study has quantitatively correlated final treatment outcome with early PET/CT treatment response or followed subjects after treatment completion to confirm relapse-free cure. Similarly, although high-resolution CT has been used to diagnose TB (25) (26) (27) (28) (29) or follow patients for treatment response (30, 31) , no study has quantitatively correlated early high-resolution CT changes with final treatment outcome.
Here, we hypothesized that quantitative changes on PET/CT or high-resolution CT scans from baseline to 2 months of drug treatment in patients with pulmonary multidrug-resistant (MDR) TB would serve as an imaging marker to predict final treatment success or failure 6 months after the end of therapy better than 2-month sputum culture conversion rates. We tested this hypothesis as a secondary endpoint in the context of a previously reported, prospective, randomized clinical trial (ClinicalTrials.gov #NCT00425113).
RESULTS
Thirty-five subjects with pulmonary MDR TB were enrolled into a twoarm, prospective, randomized clinical trial comparing metronidazole and placebo in combination with an optimized background regimen, with overall results already reported (32) . Four subjects did not complete all prespecified PET/CT and high-resolution CT scans and were excluded. The baseline characteristics of these subjects have been previously published and include median age 37 years, 81% male, 48% having far advanced disease, 52% having cavitary disease by chest x-ray, and 68% having bilateral disease. In the analyses presented here, four additional subjects were excluded: three because of incomplete followup data and one because of corruption of the PET imaging file, leaving 28 subjects for analyses. All subjects were treated for about 18 months after sputum culture conversion per World Health Organization (WHO) guidelines, then followed for an additional 6 months after the end of therapy for final treatment outcomes. At 6 months after end of therapy, four subjects were identified as treatment failures. Of these, one had an excellent radiological response at 2 months but subsequently failed treatment because of poor adherence. Another patient's sputum culture converted by 2 months but subsequently developed positive cultures again while that patient was still on treatment. The other two patients never showed sputum culture conversion. All subjects were grouped together for this analysis, rather than by study drug arm.
CT reader study Baseline, 2-month, and 6-month high-resolution CT scans were evaluated by three independent radiologists for analysis of 10 different active TB-associated radiographic features in each sextant of the lung (33) . Individual features were scored using a semiquantitative 0 to 4 scale representing quartiles of percent involvement of the indicated sextant (27, 34) , allowing a maximum score of 40. Between-reader variability in feature scores was large, so we engaged a fourth radiologist to adjudicate the feature values. The sum of all features from the adjudicated scores was used as the estimate of total disease burden for each study visit. Among the 10 CT features evaluated by the radiologists, changes (from baseline to 6 months) in three of them (that is, bronchial thickening, consolidations, and cavities) were significantly associated with treatment outcome (P < 0.05 for the change from baseline to month 6; fig. S1 ). Figure 1A shows a waterfall plot of patient total disease burden by CT scan as defined by the radiologists at baseline and log 2 fold changes at 2 and 6 months, sorted by the changes at 6 months. Failure was not more likely in patients with more severe baseline disease, whereas log fold change from baseline was somewhat associated with outcome. Receiver-operator characteristic (ROC) curve analysis of change in disease burden scores as a predictor of final treatment outcome gave areas under the ROC curve (AUCs) of 0.78 (95% CI, 0.52 to 1.0) at 2 months ( Fig. 2A) and 0.82 (95% CI, 0.58 to 1.0) at 6 months (Fig. 2B ). The subject with a good initial radiological response, fig. S1 . (B) Waterfall plot of change in automated CT abnormal volumes and correlation with treatment outcomes. Automated extraction of abnormal lung density within the thorax from −100 to +200 Hounsfield units (HU). Custom software was used to extract all abnormal lung density data and compute volumes across various density ranges. Top panel shows baseline volume of disease, and the middle and bottom panels show the log 2 fold change at 2 and 6 months, respectively. (C) Waterfall plot of change in PET total activity and correlation with treatment outcomes. Total activity across the thorax (excluding the heart) was evaluated by two separate radiologists by delineating regions of interest (ROIs) encompassing visually identified disease and exporting total activity in units of standardized uptake value (SUV). Baseline extent of disease and log 2 fold changes are shown at top and bottom (2 months). In all panels, dark green bars represent subjects with confirmed culture-negative status 6 months after discontinuing TB chemotherapy, light green bars represent subjects self-reporting no disease recurrence but without confirmatory cultures, and red bars represent patients with cultureconfirmed disease recrudescence. Asterisk represents a patient who was initially successful on treatment but became noncompliant after 6 months and subsequently failed. who subsequently failed, was documented to have been poorly adherent to therapy after the first 6 months. Excluding this subject, the AUC increased to 0.92 (95% CI, 0.79 to 1.0) at 2 months, and 0.93 (95% CI, 0.81 to 1.0) at 6 months.
Concordance correlation coefficients between the three readers across the 10 features were generally low, with values of 0.72, 0.46, and 0.68 for the concordance between readers 1 and 2, 1 and 3, and 2 and 3, respectively, for total disease burden. Results were similarly low when evaluating concordance of change from baseline to 6 months, with values of 0.55, 0.63, and 0.58 for the concordance between readers 1 and 2, 1 and 3, and 2 and 3, respectively (tables S1 to S5).
CT automated algorithm
We also developed a quantitative software algorithm to computationally extract the volume of diseased lung. The lung region was segmented by sequentially removing external contiguous structures including bone and soft tissues of the chest and back walls (Fig. 3A) . This was followed by automated detection of the carina (the point at which the trachea bifurcates into the left and right mainstem bronchi) and growing of contiguous areas of low radiodensity (less than −350 HU) and assigning these as lung-associated. A third step that relabeled high-density voxels as lung voxels within the thorax using the ribs as a boundary was implemented because of the extensive disease and collapse in many subjects. Histograms of lung voxels according to HU radiodensity were exported. These histograms revealed prominent abnormal density in a window ranging from −500 to +200 HU that appeared to be diseaseassociated. Visually, this abnormal density appeared to capture most of the apparent disease from the CT scans, although this window of density also captured larger airways and blood vessels present within the lung (Fig. 3B) . Summing the total volume of abnormal high density (−100 to +200 HU) for each study visit allowed us to calculate the baseline volume and log 2 fold change in volumes at 2 and 6 months, as shown in the waterfall plots in Fig. 1B , ranked according to log fold changes at 6 months.
Similar to reader scores, baseline severity of disease was not predictive of final treatment outcome, but change in abnormal CT volume was somewhat predictive at 2 months and more predictive at 6 months. In the ROC analysis, the decrease in overall automated abnormal density CT volume at 2 months had an AUC of 0.80 (95% CI, 0.59 to 1.0). At 6 months, log fold change in overall abnormal volume gave an AUC of 0.97 (95% CI, 0.91 to 1.0). This seemingly large increase in AUC is due to the small numbers in our analysis and is not statistically significantly different, only representing a change in four subjects, from 19 of 24 correctly classified at 2 months to 23 of 24 at 6 months (Table 1) .
It is likely that abnormal densities at HU −500 to +200 become less dense as they return to normal lung tissue. Hence, the volume of the densest lesions may be more sensitive to improvement than the total volume of abnormal lung. The AUC of the volume of harder abnormal lesions (HU density −100 to +200) increased to 0.91 (95% CI, 0.78 to 1.0) at 2 months ( Fig. 2A) , with a threshold that maximized the sum of sensitivity and specificity corresponding to a cross-validated sensitivity of 0.79 and specificity of 0.75 (Table 1) . At 6 months, the AUC of harder abnormal lesions was 0.98 (95% CI, 0.93 to 1.0) ( Fig. 2A) , with an optimal sensitivity of 0.96 and specificity of 0.75 (Table 1) . This was similar to the AUC for overall abnormal lesions. If the subject with poor adherence was excluded, AUC for harder lesions at 2 months decreased slightly to 0.88 (95% CI, 0.73 to 1.0) and increased slightly at 6 months to 0.99 (95% CI, 0.95 to 1.0).
PET changes during drug therapy
Most obvious abnormalities in these subjects' lungs showed higher than background rates of FDG uptake. Maximum SUVs observed were as high as 10 to 12, but there were also examples of lesions that did not take up FDG, although generally these looked like old lesions from previous TB episodes that did not change over the course of the study. Cavities and their associated processes showed substantial uptake, although this was often heterogeneous across the circumference of the cavity. Small nodular lesions generally showed lower uptake, although the SUVs were not corrected for partial volume effects, so this may not be general. Lesions within most subjects showed substantial decreases in FDG avidity at 2 months after treatment initiation (Fig. 4) . To quantify this effect, two nuclear medicine readers independently delineated three-dimensional ROIs from each PET scan (using MIM Maestro software version 5.6.5, MIM Software Inc.) and determined total activity within these ROIs at baseline and at 2 months of treatment. Concordance correlation coefficients between the two readers were high at baseline (0.89), at 2 months (0.89), and for the change between baseline and 2 months (0.95). Because of the high degree of correlation, only the scores of reader 2 were subsequently used for the analysis. Both readers found that most subjects had at least a 50% decrease in overall FDG avidity at 2 months (Fig. 1C) , compared with relatively modest changes in CT abnormalities (Fig. 1B, middle) .
The aggregate statistic of total activity (Table 1) did not reflect the heterogeneity of response we observed even within individual patients (Fig. 1C) , which appears to be more highly correlated with lesion type. An example of this is shown in Fig. 4 , where the bulk of parenchymal lesions in the right lower lobe of this patient showed marked resolution, whereas a collapsed middle lobe showed a considerably slower response (the SUV max in this region increased from 7 to 8 during this time interval against a background of overall disease resolution). Fig. 3 . Automated extraction of abnormal density associated with TB disease. (A) Rendering of intermediate steps in extracting lung voxels from CT scans. The outermost layers are first removed to the level of the ribs, followed by removal of skeletal features to identify the thorax region. The lung is then assigned by seeding from the carina and growing outward using thresholding to avoid mediastinal structures and lower hard organs. Finally, these regions are grown out toward the ribs using a second thresholding function to recapture density in areas of extensive consolidation and collapse. (B) Flat rendered output of disease-associated voxels from one subject at study entry (top), 2 months (middle), and 6 months (bottom) showing voxels from −500 to +100 HU.
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Total activity at baseline and the corresponding log 2 fold change at 2 months for each subject are shown by waterfall plot, ranked according to the change at 2 months (Fig. 1C) . Baseline severity again did not correlate with treatment outcome. Except for the one subject with poor adherence, all other treatment failure subjects grouped to the right, indicating either an increase in activity or minimal changes, at 2 months. In the ROC analysis, PET AUC was 0.86 (95% CI, 0.59 to 1.0) ( Fig. 2A) , with an optimal threshold selection that gave a sensitivity of 0.96 and specificity of 0.75 (Table 1) . When the poorly adherent subject was excluded, the AUC increased to 1.0.
Comparative analysis of markers of successful treatment As in other trials, sputum smear and culture at 2 months was only somewhat effective at predicting long-term outcome in our study (Table 1) . In comparing the sensitivities of the different radiological and laboratory modalities with respect to treatment outcome, PET at 2 months and CT at 6 months were better than liquid culture at 2 months (P = 0.008 and P = 0.016, respectively), but CT scan at 2 months was not. Changes in PET at 2 months and CT at 2 or 6 months were also not statistically different from solid culture or sputum smear conversion at 2 months.
Lesion density analysis
Abnormal lung density in these subjects spanned a wide range of radiodensity (from −500 to +300 HU) and represented an array of different pathological abnormalities. We examined the correlation of these different densities with the semiquantitative values from the reader study to look for an association between lesion types and density. Cavities, consolidations, and fibrosis all showed significant positive associations with the higher-density abnormalities, whereas the smaller nodular lesions all showed stronger correlations with the lower HU densities (Fig. 5) . The four densest lesions were consolidation, cavity, fibrosis, and bronchial thickening, which overlapped with the three CT reader features (bronchial thickening, consolidation, and cavity; fig. S1 ) that predicted treatment outcome.
DISCUSSION
Extensive efforts have been made to identify biomarkers for TB that can reliably identify different stages of disease (latent versus active), measure degree of treatment response (cured versus failing), quantitate risk of disease activation or relapse, or measure protective immunity, for example, from vaccination (1, 35) . A validated biomarker not only would have major implications for routine clinical care but also could be applied to clinical trials of new drugs, vaccines, or diagnostics as a surrogate endpoint to shorten the overall duration of the trials. The current biomarker for which there is the greatest experience in predicting nonrelapsing cure is sputum culture conversion at 2 months of treatment (36), with one analysis arguing that these data are robust enough Table 1 . Sensitivity and specificity of 2-month sputum culture conversion compared to CT and PET scan changes for predicting treatment outcomes. Heterogeneity of PET and CT responses in a single subject at study entry and after 2 months of treatment. This scan shows a subject with right middle and lower lobe disease and no involvement of the left lung. In this representation, voxels between −100 and 200 HU are labeled gray (smoothed for clarity in the top views but unsmoothed from the primary data in the lower views). FDG uptake is represented by a red to yellow scale ranging from an SUV of 4 to 8. This subject had a collapse of the right middle lobe and extensive abnormalities in the right lower lobe posteriorly. These parenchymal abnormalities resolved at the 2-month time point by CT and had minimal FDG uptake at 2 months, whereas the collapse of the middle lobe retained FDG uptake and showed only minimal resolution.
Modality
to serve as a surrogate endpoint in new drug registration trials (37) . Despite this, the low sensitivity and specificity of culture in one metaanalysis (2) show that there is still much room for improvement. The objective of our study was to evaluate whether candidate imaging markers would better predict final treatment outcome in pulmonary MDR TB subjects than 2-month sputum culture conversion rates. We examined three different methodologies-semiquantitative CT readings at 2 and 6 months, automated CT quantitation at 2 and 6 months, and quantitative PET analysis at 2 months. In our analysis, change in PET total activity from baseline to 2 months and change in automated CT quantitation of abnormal lung volume from baseline to 6 months both predicted final treatment outcome 6 months after end of therapy reasonably well. Although both PET at 2 months and automated CT at 6 months were more sensitive than sputum smear or solid culture conversion at 2 months, these differences were not statistically significant, possibly because of the small sample size in our study. Future studies should evaluate CT/PET imaging with a larger sample size; on the basis of the observed differences in sensitivity between PET and solid culture conversion (at 2 months), a sample size of 60 treatment successes would be required to achieve 90% power. Our sample size of 24 treatment successes only gives a power of about 32%. Thus, in this preliminary, hypothesis-generating analysis with small patient numbers, the results of PET scan changes at 2 months and CT scan changes at 6 months suggest that these are potential imaging markers of nonrelapsing cure. The expense of PET and CT precludes their widespread use in patient management, but this technology has expanded to many middleincome countries, where TB is endemic and is available for use in clinical trials. These techniques may provide useful phase 2 endpoints or intermediate endpoints in a multistage, multiarm study. Alternatively, they may offer information that more efficiently identifies active drugs and drug combinations before undertaking a large and expensive phase 3 study.
The nature and the magnitude of the PET and CT characteristics encountered in this cohort also suggest that additional metrics that describe the heterogeneity of the treatment response may be of considerable use in characterizing responses to specific drugs and combining them in a more rational way. The spectrum of lesion types and the response of these lesions to treatment reflect a variety of host and bacterial factors that contribute to ultimate outcome. A more detailed characterization of the response rates of specific lesion types will require a larger data set and better analytical tools but offers an attractive extension of the methodology developed here. The magnitude of the PET response at 2 months, and the reproducibility of its measurement, supports looking even earlier for characteristic changes in radiologic features associated with sterilizing cure.
The primary limitation of our analysis is our small total sample size, which limits the power of our comparisons. In addition, the small number of subjects who failed treatment precluded further, more indepth analyses of factors associated with failure and also which, if any, of the 10 CT reader features were most associated with failure. Reader variability was high for most features that were semiquantitatively evaluated, an observation similar to that in oncology reader studies. In oncology, variability between readers has been highest in complex lesions with poorly defined margins and most concordant when analyzing well-circumscribed tumors (38) . TB lesions are very similar to complex tumors, so our concordance coefficients between readers were not that different from similar studies in oncology (39, 40) . Various strategies have been identified in oncology to attempt to minimize intraobserver variability; larger numbers of subjects and larger numbers of readers have had some success. More encouraging computational image analysis Histograms of voxels from the automated extraction were divided into sextants according to their position relative to the carina, and these were compared to the corresponding sextant-level semiquantitative estimates of specific features from the radiologist readers. The vertical columns consist of windows 100 HU wide from the computed histograms, and the horizontal rows correspond to the 10 individual features scored by the radiologists. Correlation is indicated by the degree of tilt of the oval as well as purple (positive) or red (negative) shading. Ovals with black triangles in the center were statistically significant at P = 0.001 after bootstrap analysis.
techniques similar to what we report here are now being more widely explored and are promising techniques for future studies (41) . Also similar to the experience in oncology (42), we found very good reader agreement in evaluating FDG PET data.
In summary, we believe that these preliminary data constitute a proof of concept of the possibility of using imaging early in the course of treatment to predict final TB treatment outcome in the context of clinical trials of new TB drugs and regimens. This is supported not only by the data in this study but also by those in our companion paper using imaging in macaques, which further suggests that PET/CT could offer a directly translatable tool for piloting human clinical trials in a highly relevant animal model (43) . In addition, our initial observations that FDG avidity changes in response to drug treatment with different kinetics in lesions representing different pathologies may offer a more meaningful way of selecting drug combinations that address the full range of pathologies observed in TB patients. Additional work is needed to confirm this concept with larger data sets to better understand how well and in what contexts this predictive imaging model works best. If validated by additional data, both PET and CT imaging have the potential to serve as surrogate endpoints in future clinical trials of new drugs, allowing a shortened total trial duration, reduced costs, and faster time to trial results and public health benefit.
MATERIALS AND METHODS

Study design
A randomized, double-blind, placebo-controlled, phase 2 trial was conducted at the National Masan Hospital in Changwon, South Korea, from 2005 to 2012 and has been previously described (32) . Adult pulmonary MDR TB subjects were enrolled and received an individualized background treatment regimen for their MDR TB for at least 18 months after sputum culture conversion, per WHO guidelines. In addition, subjects were randomized to add 500 mg of metronidazole three times daily versus placebo for the initial 2 months. Subjects were followed until 6 months after the end of therapy for final treatment outcomes.
CT reader study A high-resolution CT scan (120 kV, 250 mA, 0.75 s, 1 mm × 1 mm slice thickness) was done at baseline, 2 months, and 6 months after treatment initiation. Three independent radiologists scored each sextant of the lung of all CT scans according to the presence of 10 features: nodules less than 2 mm, centrilobular nodules/linear lesions 2 to 4 mm thick, tree-in-bud opacities, 4-to 10-mm nodules, consolidations, cavities, ground glass opacities, bronchial thickening, collapse, and fibrosis (33, 34) . Images were scored for each feature according to the percent involvement in each lung sextant based on the following scale: 0 = no involvement, 1 = 1 to 25%, 2 = 26 to 50%, 3 = 51 to 75%, 4 = 76 to 100%. A fourth radiologist evaluated the scores of the three primary radiologists to provide an adjudicated score by independently reviewing the three scores and CT images.
CT automated algorithm
With an automated CT structure analysis algorithm developed inhouse, the pulmonary CT scan was categorized by voxels into normal lung, abnormal lung, and nonlung voxels. The initial lung region was determined by defining a series of layers in a first pass, performing "layered segmentation." In this pass, a combination of adaptive thresholding, three-dimensional region growing, and component labeling separated the subject's body from the background and any external objects (for example, clothing), then successively peeled off skin, muscles and fat, skeletal system, and other organs, leaving only low (less than −350) HU intensity voxels of the lungs and trachea. Lung sextants were then defined by first locating the carina, above which were the upper left and right sextants. The rest of the lungs were then divided equally into middle and lower left and right sextants, respectively, with the volume of abnormal voxels in each sextant computationally defined.
Locating the carina
The carina may be difficult to locate in extensive TB disease, particularly under conditions of lung collapse. In collapse, the opposite lung often expands, resulting in gross deformations to the position and layout of the lungs and trachea. To locate the carina under such conditions, several techniques were used including contouring, shape analysis, and fuzzy reasoning.
The first step was to identify a valid seed point in the trachea from which to start the carina tracking process. Because the trachea is a nearly vertical tube filled with air (low HU values) with an expected size range (typically 2 to 4 cm in diameter), we performed contour analysis on the various CT slices and extracted the location and size of ellipsoidal shapes. The individual ellipses are then stacked into tubular shapes upon which length, roundness, and regularity metrics were computed for each resulting tube. With fuzzy metrics, a score was assigned to each tube and the one corresponding to the trachea was thus selected.
Once a good seed was selected for the trachea, directed cross-sectional analysis was used to track the trachea until the first bifurcation. The center of the bifurcation was recorded as the carina location. With the carina location information, region growing, and component labeling, lowdensity lung voxels were further labeled as belonging to the trachea or left or right lung.
Lung segmentation
Once the sextants were defined, the rib cage boundary was used to grow the lung regions, particularly when the Hounsfield intensity of the lung region adjoining the ribs was high because of infection/consolidation. Knowledge of the arteries, veins, and aorta in the heart-lung boundary region was used to distinguish between abnormal lung tissue and nonlung tissue. The resulting lung is segmented into upper (defined by the area above the carina), middle, and lower (lung below the carina divided in half) sextants in the left and right lungs.
FDG PET
In addition to the high-resolution CT, a PET/CT scan (CT resolution 1.17 mm × 1.17 mm × 3 mm) with FDG was done at baseline and 2 months after treatment initiation. Two independent nuclear radiologists identified all regions of uptake within the lung to provide a total activity using SUV for a given subject at baseline and at 2 months. Standardized update value at time point t is defined as follows:
where c is the measured tissue radioactivity concentration (MBq/kg) and injected activity is the amount of radiation (MBq) injected extrapolated to time point t. Total activity was calculated by exporting histograms of ROIs according to SUV values and calculating the product of the fractional proportion and the SUV value, the aggregate sum of which was then multiplied by the ROI volume to generate the total activity.
Statistical analysis
Subjects were defined as "success" 6 months after end of therapy if they were clinically without disease and had a sputum culture with no growth. "Probable success" was defined as a subject who was a clinical success but without microbiologic confirmation. All other subjects were defined as "failure." CT reader scores from the adjudicating radiologist were used to evaluate the diagnostic performance. The adjudicated scores for a given feature were averaged across sextants for each subject (at each time point) to account for subjects who did not undergo imaging of the entire lung. These averaged scores were summed to produce the total CT reader score.
Concordance correlation coefficients (44) describe the agreement in the burden of disease for each feature as evaluated by the three primary radiologists and also by the two nuclear medicine specialists. Log 2 fold changes from baseline to 2 months and from baseline to 6 months were computed to describe the relative improvement or worsening of disease. Waterfall plots and nonparametric ROC analysis visualized the relationship between imaging biomarkers and ultimate treatment outcome. Nonparametric AUCs evaluated statistical significance (45) .
To compare the sensitivities and specificities of the imaging biomarkers with those of culture, thresholds were defined for each imaging biomarker. For each modality and time point (log fold change from baseline to 2 and 6 months), the threshold corresponding to the largest sensitivity + specificity was selected. To adjust for overestimation of these parameters due to optimal selection, cross-validated sensitivity and specificity values were reported. Test statistics comparing these values to culture were estimated using a cross-validation procedure as well.
Correlation plots were constructed using Spearman rank correlations using the corrplot function in R (46) based on the sextant-level data at baseline. P values were obtained using a bootstrap procedure to account for multiple sextants per subject. All statistical analyses were conducted using R version 2.15.1 and Stata version 12.
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